Skip to search formSkip to main contentSkip to account menu

NOV120101

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

poziotinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstract OT3-01-10: A prospective, open-label, single-arm, multi-center, phase II exploratory study to evaluate the efficacy and safety of poziotinib (NOV120101) in patients with HER2-positive…
Background: Poziotinib is a novel, oral, irreversible pan-HER inhibitor that has shown promising clinical activity in Phase 1… 
Review
2015
Review
2015
A phase II, single-arm, efficacy and safety study of poziotinib (NOV120101) in Korean patients with advanced or metastatic lung adenocarcinoma who have acquired resistance to epidermal growth factor…
8085 Background: Poziotinib is an oral irreversible inhibitor of EGFR, HER2 and HER4, and has shown preclinical activity in lung… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)